Conversion from Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results from the Randomized ZEUS Study
This paper prevents further results from a randomized controlled trial of mandatory conversion from cyclosporine to everolimus. There remains a higher acute rejection rate in the everolimus-treated patients. However, renal function remained better in the everolimus arm. As in many such trials, a significant number of patients treated with everolimus had to change to other medications, either because of side effects or adverse events.